nach oben

International Journal of Diabetes in Developing Countries

Erschienen in:

01.03.2013 | Original Article

Relationship of PON1 activity and hsCRP concentration with disease status in patients with type 2 diabetes mellitus with and without retinopathy

verfasst von: Yasemin Ustündag Budak, Müberra Akdogan, Kagan Huysal

Erschienen in: International Journal of Diabetes in Developing Countries | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to determine paraoxonase-I activity (PON 1), lipid profile and hsCRP in type 2 diabetic patients with and without retinopathy who had the same duration of the disease (10 years), to determine the correlations among these parameters and to compare these values with those measured in normal control subjects. Fifty four subjects (mean age 58 ± 7 years, men / women 25/29) with type 2 diabetes (T2DM) with proliferative diabetic retinopathy (PDR) (N = 25) and without retinopathy (nonDR) (N = 29) were included in the study. Twenty four healthy subjects were selected as control group (61 ± 6 years, men / women 10/14). Paraoxonase and arylesterase activities were measured spectrophotometrically. The DM + PDR group had lower paraoxonase activity (199 ± 39 vs. 258 ± 60 U/L, P < 0.05) and higher hsCRP (5.8 ± 4.9 vs. 3.2 ± 1.1 mg/L, P < 0.05) than the healthy control group. In patients with DM, paraoxonase activity was positively associated with HDL cholesterol and negatively associated with serum glucose, total cholesterol, and LDL cholesterol. Although hsCRP was elevated and paraoxonase was decreased in type 2 diabetic patients, a link between oxidation and inflammation and the development of diabetic retinopathy remains unexplored.

American Academy of Ophthalmology. 2003. Diabetic retinopathy preferred practice pattern. Accessed Nov 24, 2006.

Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. Retinopathy in diabetes. Diabetes Care. 2004;27 Suppl 1:84–7.CrossRef

Lyons TJ, Li W, Wells-Knecht MC, Jokl R. Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes. 1994;43:1090–5.PubMedCrossRef

Garner A. Histopathology of diabetic retinopathy in man. Eye. 1993;7:250–3.PubMedCrossRef

Lyons TJ, Baynes JW, Patrick JS, Colwell JA, Lopes-Virella MF. Glycosylation of low density lipoprotein in patients with type 1 (insulin-dependent) diabetes: correlations with other parameters of glycaemic control. Diabetologia. 1986;29:685–9.PubMedCrossRef

Pennathur S, Heinecke JW. Mechanisms for oxidative stress in diabetic cardiovascular disease. Antioxid Redox Signal. 2007;9:955–69.PubMedCrossRef

Ravandi A, Kuksis A, Shaikh NA. Glucosylated glycerophosphoethanolamines are the major LDL glycation products and increase LDL susceptibility to oxidation: evidence of their presence in atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:467–77.PubMedCrossRef

Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low densıty lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26:892–904.PubMedCrossRef

Durrington P, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473.PubMedCrossRef

10.

Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286:152–4.PubMedCrossRef

11.

Aviram M. Introduction to the serial review on paraoxonases, oxidative stress, and cardiovascular diseases. Free Radic Biol Med. 2004;37:1301–3.PubMedCrossRef

12.

Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998;423:57–60.PubMedCrossRef

13.

Pennathur S, Heinecke JW. Mechanisms of oxidative stress in diabetes: implications for the pathogenesis of vascular disease and antioxidant therapy. Front Biosci. 2004;9:565–74.PubMedCrossRef

14.

Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci. 2004;107:435–47.PubMedCrossRef

15.

Hofer SE, Bennetts B, Chan AK, Holloway B, Karschimkus C, Jenkins AJ, et al. Association between PON 1 polymorphisms, PON activity and diabetes complications. J Diabetes Complications. 2006;20:322–8.PubMedCrossRef

16.

van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm. 2010;15.

17.

Pino SC, Kruger AJ, Bortell R. The role of innate immune pathways in type 1 diabetes pathogenesis. Curr Opin Endocrinol Diabetes Obes. 2010;17:126–30.PubMedCrossRef

18.

Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism. 1998;47:598–602.PubMedCrossRef

19.

Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33:S62–S69

20.

Mackness B, Durrinton P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly prospective Study. Circulation. 2003;107:2775–9.PubMedCrossRef

21.

Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clim Biochem. 1992;30:391–5.

22.

Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450–2.PubMed

23.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–34.PubMedCrossRef

24.

Chase HP, Cooper S, Osberg I, Stene LC, Barriga K, Norris J, et al. Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes. 2004;53:2569–73.PubMedCrossRef

25.

Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care. 1999;22:1971–7.PubMedCrossRef

26.

van Hecke MV, Dekker JM, Nijpels G, Moll AC, Heine RJ, Bouter LM, et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia. 2005;48:1300–6.PubMedCrossRef

27.

Mackness B, McElduff P, Mackness MI. The paraoxonase-2-310 polymorphism is associated with microvascular complications in diabetes mellitus. J Intern Med. 2005;258:363–8.PubMedCrossRef

28.

Koch M, Hering S, Barth C, Ehren M, Enderle MD, Pfohl M. Paraoxonase 1 192 Gln/Arg gene polymorphism and cerebrovascular disease interaction with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2001;109:141–5.PubMedCrossRef

29.

Deakin SP, James RW. Genetic and environmental factors for modulating serum concentrations and activities of the antioxidant enzyme paraoxonase. Clin Sci. 2004;107:435–7.PubMedCrossRef

30.

Lee CT, Rowley K, Jenkins AJ, O’Dea K, Itsiopoulos C, Stoney RM, et al. Paraoxonase activity in Greek migrants and Anglo-Celtic persons in the Melbourne collaborative cohort survey: relationship to dietary markers. Eur J Nutr. 2005;44:223–30.PubMedCrossRef

31.

Agachan B, Yilmaz H, Karaali Z, Isbir T. Paraoxonase 55 and 192 polymorphisms and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin-dependent diabetes. Cell Biochem Funct. 2004;22:163–8.PubMedCrossRef

32.

Sozmen B, Delen Y, Girgin FK, Sozmen EY. Catalase and paraoxonase in hypertensive subjects with Type 2 diabetes mellitus: correlation with glycaemic control. Clin Biochem. 1999;32:423–7.PubMedCrossRef

33.

Kopprasch S, Pietzsch J, Kuhlisch E, Graessler J. Lack of association between serum paraoxonase-1 activities and increased oxidised low density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes. J Clin Endocrinol Metab. 2003;288:1711–6.CrossRef

34.

Mohanty P, Ghanim H, Hamouda W, Aljada A, Garg R, Dandona P. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. Am J Clin Nutr. 2002;75:767–72.PubMed

35.

Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol. 2009;3:S14–20.CrossRef

36.

Kalogerakis G, Baker AM, Christov S, Rowley KG, Dwyer K, Winterbourn C, et al. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease. Clin Sci. 2005;108:497–506.PubMedCrossRef

37.

Baynes JW. Chemical modification of proteins by lipids in diabetes. Clin Chem Lab Med. 2003;41:1159–65.PubMedCrossRef

38.

Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM, et al. Glycation impairs high-density lipoprotein function. Diabetologia. 2000;43:312–20.PubMedCrossRef

39.

Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, Hokanson JE, et al. Paraoxonase genotypes, lipoprotein lipase activity and HDL. Arterioscler Thromb Vasc Biol. 1996;16:1243–9.PubMedCrossRef

40.

Sozmen EY, Sozmen B, Delen Y, Onat T. Catalase/superoxide dismutase (SOD) and catalase/paraoxonase (PON) ratios may implicate poor glycemic control. Arch Med Res. 2001;32:283–7.PubMedCrossRef

41.

Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 1995;15:1812–8.PubMedCrossRef

Titel: Relationship of PON1 activity and hsCRP concentration with disease status in patients with type 2 diabetes mellitus with and without retinopathy
verfasst von: Yasemin Ustündag Budak
Müberra Akdogan
Kagan Huysal
Publikationsdatum: 01.03.2013
Verlag: Springer-Verlag
Erschienen in: International Journal of Diabetes in Developing Countries / Ausgabe 1/2013
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI: https://doi.org/10.1007/s13410-012-0103-1

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Relationship of PON1 activity and hsCRP concentration with disease status in patients with type 2 diabetes mellitus with and without retinopathy

Abstract

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

International Journal of Diabetes in Developing Countries

Urinary IgG is a pure strong indicator of diabetic nephropathy than microalbuminuria in type 2 diabetic patients

Application of community periodontal index of treatment need (CPITN) in a group of insulin dependent diabetes mellitus (IDDM) patients

The direct cost of diabetic foot management in some of private hospitals in Jeddah, Saudi Arabia

Berardinelli Seip congenital lipodystrophy presenting with neonatal diabetes mellitus due to a mutation in the AGPAT2 gene

Antidiabetic and antioxidant effect of Swietenia macrophylla seeds in experimental type 2 diabetic rats